Chemotherapy for Breast Cancer

Phase-Based Progress Estimates
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PABreast Cancer+23 MoreChemotherapy - Other
All Sexes
What conditions do you have?

Study Summary

This trial is testing whether fasting could improve outcomes for obese breast cancer patients receiving chemotherapy.

Eligible Conditions
  • Breast Cancer
  • Stage 1 Breast Cancer
  • Stage IA Breast Cancer
  • Stage IB Breast Cancer
  • Stage II Breast Cancer
  • Stage IIA Breast Cancer
  • Stage IIB Breast Cancer
  • Stage III Breast Cancer
  • Stage IIIA Breast Cancer
  • Stage IIIB Breast Cancer
  • Ductal Breast Carcinoma In Situ
  • HER2-negative Breast Cancer
  • Hormone Receptor-positive Breast Cancer
  • Stage 2 Breast Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Through study participation; approximately 6 months

Month 6
Proportion of patients who can adhere to to intermittent fasting > 80% of days

Trial Safety

Safety Progress

1 of 3

Side Effects for

14%Alanine aminotransferase increased
14%White blood cell count decreased
10%Aspartate aminotransferase increased
10%Platelet count decreased
10%Neutrophil count decreased
5%Musculoskeletal pain
5%Back pain
This histogram enumerates side effects from a completed 2014 Phase 4 trial (NCT02000531) in the Erlotinib-Chemotherapy ARM group. Side effects include: Nausea with 29%, Leukopenia with 19%, Vomiting with 14%, Neutropenia with 14%, Alanine aminotransferase increased with 14%.

Trial Design

1 Treatment Group

Treatment (Intermittent Fasting)
1 of 1

Experimental Treatment

55 Total Participants · 1 Treatment Group

Primary Treatment: Chemotherapy · No Placebo Group · N/A

Treatment (Intermittent Fasting)Experimental Group · 2 Interventions: Short-Term Fasting, Chemotherapy · Intervention Types: Other, Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study participation; approximately 6 months

Who is running the clinical trial?

Thomas Jefferson UniversityLead Sponsor
410 Previous Clinical Trials
136,040 Total Patients Enrolled
5 Trials studying Breast Cancer
607 Patients Enrolled for Breast Cancer
National Cancer Institute (NCI)NIH
13,156 Previous Clinical Trials
41,163,551 Total Patients Enrolled
928 Trials studying Breast Cancer
1,536,849 Patients Enrolled for Breast Cancer

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Is enrollment for this investigation currently open?

"Affirmative. has information that suggests this experiment is presently enrolling volunteers, with the first posting date being July 28th 2022 and the last update occurring on August 2nd 2022. The research project needs to recruit 55 individuals from a single medical location." - Anonymous Online Contributor

Unverified Answer

What is the scope of recruitment for this research endeavor?

"Affirmative. The particulars of this clinical trial, which was posted on July 28th 2022, are listed as active recruitment status according to information hosted on This medical study requires the participation of 55 individuals from a single site." - Anonymous Online Contributor

Unverified Answer

What risks are associated with undergoing Chemotherapy?

"After careful consideration, the safety rating of chemotherapy was determined to be a 2 due it's status as Phase 2 clinical trial. Thus far, there is sufficient data to suggest that it is safe but not enough evidence to support its efficacy." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.